Astria Therapeutics
ATXS
ATXS was delisted on the 22nd of January, 2026.
35 hedge funds and large institutions have $63.8M invested in Astria Therapeutics in 2021 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 13 increasing their positions, 14 reducing their positions, and 28 closing their positions.
3.23% more ownership
Funds ownership: 52.99% → 56.22% (+3.2%)
7% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 14
26% less capital invested
Capital invested by funds: $86M → $63.8M (-$22.3M)
26% less call options, than puts
Call options by funds: $262K | Put options by funds: $354K
40% less funds holding
Funds holding: 58 → 35 (-23)
82% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$6.5M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.01M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$2.6M |
| 4 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$2.2M |
| 5 |
Renaissance Technologies
New York
|
+$445K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$6.73M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$3.75M |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$2.48M |
| 4 |
Millennium Management
New York
|
-$974K |
| 5 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$398K |
ATXS Hedge Fund Activity: Q3 2021 in Review
35 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q3 2021, worth a combined $63.8M — down 26% from $86M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of ATXS and 5 opened new positions — a net loss of 23 holders — while 14 trimmed existing stakes and 13 added.
The largest buyer was Perceptive Advisors, adding an estimated $6.5M. The largest seller was Logos Global Management, exiting entirely with an estimated $6.73M sold.
- 35 institutional investors held Astria Therapeutics (ATXS) as of Q3 2021, down from 58 in Q2 2021.
- Funds reported $63.8M of Astria Therapeutics stock for Q3 2021, down 26% quarter-over-quarter.
- 5 funds opened new Astria Therapeutics positions in Q3 2021 and 28 closed out, a net change of -23 holders.
- The largest Astria Therapeutics buyer in Q3 2021 was Perceptive Advisors, an estimated $6.5M added.
- The largest Astria Therapeutics seller in Q3 2021 was Logos Global Management, an estimated $6.73M sold.
Based on aggregated 13F filings for Q3 2021.